microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1

Figures & data

Table 1. Relationship between miR-877-5p expression and clinical parameters of patients with PCa

Variables	Cases (n = 101)	miR-877-5p expression		P-value
		Low (n = 53)	High (n = 48)
Age				0.940
≤60	53	28	25
>65	48	25	23
Tumor size				0.849
≤3 cm	62	33	29
>3 cm	39	20	19
PSA				0.196
≤10 ng/ml	65	31	34
>10 ng/ml	36	22	14
Surgical margin				0.433
Negative	72	36	36
Positive	29	17	12
Prostate volume				0.878
≤50 ml	66	35	31
>50 ml	35	18	17
TNM stage				0.011
I–II	54	22	32
III	47	31	16
Gleason score				0.047
≤7	68	31	37
>7	33	22	11

PSA, prostate-specific antigen; TNM, tumor-node-metastasis; PCa, prostate cancer.

Table 2. Multivariate Cox analysis of clinical characteristics in relation to overall survival

Characteristics	Multivariate analysis
	HR	95% CI	P
miR-877-5p	3.880	1.367–11.011	0.011
Age	1.001	0.433–2.313	0.998
Tumor size	1.563	0.644–3.794	0.324
PSA	2.240	0.909–5.520	0.080
Surgical margin	1.006	0.379–2.669	0.990
Prostate volume	1.461	0.623–3.429	0.384
TNM stage	4.778	1.334–17.106	0.016
Gleason score	2.091	1.226–7.161	0.016

Figure 1. miR-877-5p is downregulated in prostate cancer. (a). Relative expression of miR-877-5p in prostate cancer tissue and normal tissue samples (n = 101). (b). miR-877-5p expression in prostate cancer cell lines and normal prostatic epithelial cell RWPE-1. n = 4. *P < 0.05, ***P < 0.001

Figure 2. The 5-year survival rate of prostate cancer patients with different miR-877-5p expression levels (log-rank test P = 0.003)

Figure 3. Proliferation of DU-145 and LNCap cells was suppressed after the upregulation of miR-877-5p compared to untreated cells. DU-145 and LNCap cells were transfected with mimic NC or miR-877-5p mimic. (a) and (b) miR-877-5p expression was determined in DU-145 and LNCap cells by qRT-PCR. n = 5. (c) and (d) Proliferative capacity of DU-145 and LNCap cells were measured by CCK-8. n = 3. (e) and (f) Migratory ability of DU-145 and LNCap cells were measured by transwell assay; n = 5. (g) and (h) Invasive ability of DU-145 and LNCap cells were detected using transwell assay. n = 5. *P < 0.05, ***P < 0.001

Figure 4. miR-877-5p interacted with FOXM1. (a) The binding site between FOXM1 and miR-877-5p is shown. (b) The correlation between miRNA-143-3p and miR-877-5p expression in prostate cancer tissues was analyzed by Spearman correlation analysis. n = 101. (c) Expression of FOXM1 was measured using qRT-PCR in DU-145 cells that were transfected with mimic NC or miR-877-5p mimic separately; n = 5. (d) Luciferase activity was examined in DU-145 cell cotransfected with miR-877-5p mimic, mimic NC, miR-877-5p inhibitor, or inhibitor NC and WT-FOXM1 or MUT-FOXM1. n = 3. **P < 0.01, ***P < 0.001